Advertisement

Topics

Kosan Biosciences Company Profile

18:19 EST 21st November 2017 | BioPortfolio

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's drug candidates have demonstrated the potential to overcome resistance after relapse and to synergize the initial activity of existing cancer therapies. Kosan's first and second generation Hsp90 inhibitor clinical programs have demonstrated antitumor activity in multiple indications. Tanespimycin (KOS-953) is a first generation geldanamycin analog prepared in Kosan's proprietary formulation. The agent is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma and HER2-positive breast cancer. In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin hydrochloride (KOS-1022) are being evaluated in Phase 1 clinical trials. Kosan's epothilone drug candidates have the potential to achieve best-in-class status. Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most widely used classes of chemotherapeutic agents. Kosan's compounds have been specially engineered to overcome resistance to taxanes and to have an attractive clinical profile. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. In February 2007, Roche and Kosan announced the selection of KOS-1584 to advance into a Phase 2 clinical development program in multiple solid tumor types. As a result, the companies have decided to discontinue development of KOS-862 and focus resources on advancing KOS-1584. Kosan has demonstrated a strong track record of achievement and productivity. Today, Kosan has four clinical candidates generating positive anticancer activity and an early-stage cancer pipeline that is advancing toward the clinic. The company is well-capitalized and has built a strong proprietary position. Kosan has demonstrated the ability to establish and maintain strong validating partnerships and has numerous additional assets for partnering. Kosan has two cooperative research and development agreements (CRADAs) with the National Cancer Institute for development of Hsp90 inhibitors. Kosan has a broad development and commercialization collaboration with Roche for the company’s epothilone program, and a worldwide licensing agreement with Pfizer for the company’s motilin agonist program. Kosan was founded in 1995 and is headquartered in Hayward, California. The company currently has approximately 80 employees.

Location

3832 Bay Center Place
Hayward
CA
94545
United States of America

Contact

Phone: 510-732-8400
Fax: 510-732-8401
Email: info@kosan.com


News Articles [575 Associated News Articles listed on BioPortfolio]

Harmony Biosciences gains US rights to pitolisant; raises $270 million

USA-based Harmony Biosciences, a part of the Paragon Biosciences corporate family, has acquired the exclusive…

Ricerca Biosciences, LLC Renamed to Concord Biosciences, LLC After Sale of Chemical Development ...

According to Clifford W. Croleyof Main Market Partners and the CEO of Concord Biosciences, "We are very pleased to focus our complete energies Read more...

Apricus Biosciences, Inc.: Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, 2017-10-10 13:00 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced...

Daily Technical Summary Reports on Drug Makers Stocks -- Apricus Biosciences, DURECT, Sucampo ...

http://dailystocktracker.com/register/ Apricus Biosciences  On Tuesday, shares in San Diego, Californiaheadquartered Apricus Biosciences Inc. recorded a trading volume of 128,247 shares. The stoc...

Head to Head Survey: DARA Biosciences

DARA Biosciences and Mallinckrodt PLC are both specialty & advanced pharmaceuticals companies, but which is the superior investment? We will contrast the two companies based on the strength of the...

Reviewing Catalyst Biosciences

Catalyst Biosciences and Fortress Biotech are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valu...

Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases

Collaboration aims to develop best-in-class anti-C3 intravitreal products with quarterly dosing frequency and better potency C3 is a clinically validated target in dry age-related macular degener...

Mallinckrodt PLC (MNK) versus DARA Biosciences (DARA) Head-To-Head Contrast

Mallinckrodt PLC and DARA Biosciences are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, instituti...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [67 Associated PubMed Articles listed on BioPortfolio]

Draft Genome Sequences of Trichophyton rubrum CMCC(F)T1i and Trichophyton violaceum CMCC(F)T3l by Illumina 2000 and Pacific Biosciences.

One strain of Trichophyton rubrum CMCC(F)T1i (=CBS 139224) isolated from onychomycosis and one strain of Trichophyton violaceum CMCC(F)T3l (=CBS 141829) isolated from tinea capitis in China were whole...

Amnesia and criminal responsibility.

Front cover.

Front cover.

Back cover.

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosup...

Companies [344 Associated Companies listed on BioPortfolio]

Kosan Biosciences Incorporated

Kosan Biosciences

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epo...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

More Information about "Kosan Biosciences" on BioPortfolio

We have published hundreds of Kosan Biosciences news stories on BioPortfolio along with dozens of Kosan Biosciences Clinical Trials and PubMed Articles about Kosan Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kosan Biosciences Companies in our database. You can also find out about relevant Kosan Biosciences Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record